GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biomark Diagnostics Inc (XCNQ:BUX) » Definitions » Shiller PE Ratio

Biomark Diagnostics (XCNQ:BUX) Shiller PE Ratio : (As of Mar. 24, 2025)


View and export this data going back to 2014. Start your Free Trial

What is Biomark Diagnostics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Biomark Diagnostics Shiller PE Ratio Historical Data

The historical data trend for Biomark Diagnostics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomark Diagnostics Shiller PE Ratio Chart

Biomark Diagnostics Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Biomark Diagnostics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Biomark Diagnostics's Shiller PE Ratio

For the Diagnostics & Research subindustry, Biomark Diagnostics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomark Diagnostics's Shiller PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biomark Diagnostics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Biomark Diagnostics's Shiller PE Ratio falls into.



Biomark Diagnostics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Biomark Diagnostics's E10 for the quarter that ended in Dec. 2024 is calculated as:

For example, Biomark Diagnostics's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-0.02/127.3637*127.3637
=-0.020

Current CPI (Dec. 2024) = 127.3637.

Biomark Diagnostics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201503 -0.015 99.789 -0.019
201506 -0.007 100.500 -0.009
201509 -0.005 100.421 -0.006
201512 -0.005 99.947 -0.006
201603 -0.016 101.054 -0.020
201606 -0.004 102.002 -0.005
201609 -0.003 101.765 -0.004
201612 -0.002 101.449 -0.003
201703 0.000 102.634 0.000
201706 -0.003 103.029 -0.004
201709 -0.004 103.345 -0.005
201712 -0.003 103.345 -0.004
201803 0.000 105.004 0.000
201806 -0.002 105.557 -0.002
201809 -0.003 105.636 -0.004
201812 -0.003 105.399 -0.004
201903 0.000 106.979 0.000
201906 -0.002 107.690 -0.002
201909 -0.002 107.611 -0.002
201912 -0.010 107.769 -0.012
202003 -0.010 107.927 -0.012
202006 -0.002 108.401 -0.002
202009 -0.003 108.164 -0.004
202012 -0.003 108.559 -0.004
202103 -0.010 110.298 -0.012
202106 -0.004 111.720 -0.005
202109 -0.002 112.905 -0.002
202112 -0.004 113.774 -0.004
202203 -0.010 117.646 -0.011
202206 -0.020 120.806 -0.021
202209 -0.010 120.648 -0.011
202212 -0.020 120.964 -0.021
202303 0.000 122.702 0.000
202306 -0.020 124.203 -0.021
202309 -0.003 125.230 -0.003
202312 -0.020 125.072 -0.020
202403 0.000 126.258 0.000
202406 -0.020 127.522 -0.020
202409 -0.010 127.285 -0.010
202412 -0.020 127.364 -0.020

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Biomark Diagnostics  (XCNQ:BUX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Biomark Diagnostics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Biomark Diagnostics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomark Diagnostics Business Description

Traded in Other Exchanges
Address
130 - 3851 Shell Road, Richmond, BC, CAN, V6X 2W2
Biomark Diagnostics Inc is a Canada-based oncology-focused company. It is engaged in the development of the early-stage cancer diagnostic technology platform. The company develops non-invasive cancer diagnostic solutions which will help to detect, monitor, and assess early cancer treatment. Its research and development are focused on the role that metabolomics plays in early cancer detection. The company's objective is to commercialize its inventive technology. and strive to increase the predictive accuracy in early-stage cancer detection.
Executives
Guoyu Huang Senior Officer
Rashid Ahmed Maula Bux Director

Biomark Diagnostics Headlines

No Headlines